


Voxilaprevir

Chemical Properties

CAS No. :	1535212-07-7
Formula:	C40H52F4N6O9S
Molecular Weight:	868.93
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Voxilaprevir is an inhibitor of hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease.
Targets(IC50)	HCV Protease

Solubility Information

Solubility	DMSO: 150 mg/mL (172.63 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: < 10 mg/mL (11.51 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+90% Saline: < 10 mg/mL (11.51 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+90% Corn oil: < 10 mg/mL (11.51 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+90% Corn Oil: 2 mg/mL (2.3 mM), Sonication is recommended. 10% DMSO+90% (20% SBE-β-CD in Saline): < 10 mg/mL (11.51 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1508 mL	5.7542 mL	11.5084 mL
5 mM	0.2302 mL	1.1508 mL	2.3017 mL
10 mM	0.1151 mL	0.5754 mL	1.1508 mL
50 mM	0.023 mL	0.1151 mL	0.2302 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Bourlière, Marc, Gordon S C , Flamm S L , et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.[J]. N Engl J Med, 2017, 376(22):2134-2146.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481